Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
10 hedge funds and large institutions have $1.27M invested in Oncobiologics, Inc. Series B Warrant in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
17% less funds holding
Funds holding: 12 → 10 (-2)
40% less capital invested
Capital invested by funds: $2.14M → $1.27M (-$864K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$99K |
| 2 |
PA
Perceptive Advisors
New York
|
-$83.9K |
| 3 |
JG
Jefferies Group
New York
|
-$63K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$10.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $456K | – | – | – |
|
|
PA
2
Perceptive Advisors
New York
| $231K | -$83.9K | -193,882 | -30% |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $208K | – | – | – |
|
|
MWNA
4
Marshall Wace North America
New York
| $125K | +$54.1K | +125,100 | New |
|
|
ACA
5
Avoro Capital Advisors
New York
| $117K | – | – | – |
|
|
PC
6
PointState Capital
New York
| $50K | – | – | – |
|
|
ACP
7
Acuta Capital Partners
Redwood City,
California
| $48K | – | – | – |
|
8
Millennium Management
New York
| $21K | -$519 | -1,200 | -3% |
|
|
MIM
9
Monashee Investment Management
Boston,
Massachusetts
| $13K | -$10.8K | -25,000 | Closed |
|
10
Morgan Stanley
New York
| $4K | – | – | – |
|
|
11
Marshall Wace
London,
United Kingdom
| – | -$99K | -125,100 | Closed |
|
|
JG
12
Jefferies Group
New York
| – | -$63K | -79,347 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$1.19K | -2,748 | -71% |
|
ONSIZ Hedge Fund Activity: Q1 2017 in Review
10 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q1 2017, worth a combined $1.27M — down 40% from $2.14M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ONSIZ and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.
The largest seller was Marshall Wace, exiting entirely with an estimated $99K sold.
- 10 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q1 2017, down from 12 in Q4 2016.
- Funds reported $1.27M of Oncobiologics, Inc. Series B Warrant stock for Q1 2017, down 40% quarter-over-quarter.
- 1 fund opened new Oncobiologics, Inc. Series B Warrant positions in Q1 2017 and 3 closed out, a net change of -2 holders.
- The largest Oncobiologics, Inc. Series B Warrant seller in Q1 2017 was Marshall Wace, an estimated $99K sold.
Based on aggregated 13F filings for Q1 2017.